source
- ArriVent's lead lung cancer drug firmonertinib fails Phase 3 trial, shares plungeArriVent BioPharma announced that its flagship EGFR inhibitor, firmonertinib, did not meet primary endpoints in a late-stage Phase 3 study for lung cancer. The trial results were released on Octobe…
- AstraZeneca launches $1 billion R&D hub in Boston’s Kendall SquareAstraZeneca opened a new research and development site in Kendall Square, Boston, marking a $1 billion investment in the U.S. biotech corridor. The Boston location underscores the company’s commit…